UpFrontPSMA: A Randomized Phase 2 Study of Sequential 177Lu‐PSMA‐617 and Docetaxel vs Docetaxel in Metastatic Hormone‐naïve Prostate Cancer (Clinical Trial Protocol)
Objective: To assess the activity and safety of sequential lutetium‐177 (177Lu)‐PSMA‐617 and docetaxel vs docetaxel on a background of androgen deprivation therapy (ADT) in men with de novo metastatic hormone‐naïve prostate cancer (mHNPC).
